Late-phase trials of targeted therapies for elevated lipoprotein(a) are nearing completion, with the first readouts expected ...
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine ...
Please provide your email address to receive an email when new articles are posted on . Muvalaplin, the first oral therapy developed to lower lipoprotein(a), did so in a phase 1 study. An extended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results